The EDC is live today — see what ships now
All studies
NCT06433752From ClinicalTrials.govRecruiting

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

REal World ExperieNce With BRIUMVI® (UblituximAB-xiiy) Treated Patients: A Longitudinal REgistry Study (ENABLE)

  • Relapsing Multiple Sclerosis
  • Multiple Sclerosis

At a glance

Phase
Phase not stated
Study type
Observational
Sponsor
TG Therapeutics, Inc.
Enrolment target
2,000
Started
22 July 2024
Main results due
1 April 2032
Study sites
111
Registry updated
23 September 2026

Can you take part?

  • Aged 18 years and over.
  • Open to any sex.
  • You need the condition being studied — healthy volunteers are not accepted.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria
Inclusion Criteria:

1. Confirmed Multiple Sclerosis (MS) diagnosis.
2. Participants who have not received any BRIUMVI® (ublituximab-xiiy) infusion prior to study start. Participants who have been prescribed BRIUMVI® (ublituximab-xiiy) but have not yet received their first infusion on Day 1 of 150 milligrams (mg) can be included.

Exclusion Criteria:

1. Have received any live or live-attenuated vaccines (including for varicella-zoster virus or measles) within 4 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration or any non-live vaccines within 2 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration.
2. Any active infection (e.g., active Hepatitis B virus \[HBV\])
3. Concurrent participation in any interventional MS trials, or planned concurrent treatment with other Multiple Sclerosis Disease Modifying Therapy (MS DMT) during the study period.

What this study is about

In the sponsor’s own words, from the registry.

The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting

Study sites(111)

  • TG Therapeutics Investigational Trial Site

    Birmingham, Alabama, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Cullman, Alabama, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Huntsville, Alabama, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Mobile, Alabama, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Gilbert, Arizona, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Phoenix, Arizona, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Scottsdale, Arizona, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Fresno, California, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Newport Beach, California, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Orange, California, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    West Hollywood, California, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Aurora, Colorado, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Basalt, Colorado, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Colorado Springs, Colorado, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Colorado Springs, Colorado, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Denver, Colorado, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Fort Collins, Colorado, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Grand Junction, Colorado, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Farmington, Connecticut, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Hartford, Connecticut, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Washington D.C., District of Columbia, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Altamonte Springs, Florida, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Boca Raton, Florida, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Clearwater, Florida, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Gainesville, Florida, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Maitland, Florida, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Miami, Florida, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Naples, Florida, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Orlando, Florida, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Pensacola, Florida, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Weston, Florida, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Atlanta, Georgia, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Atlanta, Georgia, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Savannah, Georgia, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Smyrna, Georgia, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Honolulu, Hawaii, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Coeur d'Alene, Idaho, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Chicago, Illinois, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Chicago, Illinois, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Evanston, Illinois, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Urbana, Illinois, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Avon, Indiana, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Roeland Park, Kansas, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Lexington, Kentucky, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Louisville, Kentucky, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Baltimore, Maryland, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Glen Burnie, Maryland, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Boston, Massachusetts, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Burlington, Massachusetts, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Norfolk, Massachusetts, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Ann Arbor, Michigan, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Detroit, Michigan, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Farmington, Michigan, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Owosso, Michigan, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Rochester Hills, Michigan, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Golden Valley, Minnesota, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Plymouth, Minnesota, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Billings, Montana, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Lincoln, Nebraska, United States

    Recruiting

  • TG Therapeutics Investigational Trial Site

    Omaha, Nebraska, United States

    Recruiting

Showing 60 of 111 sites — filter to narrow it down. 111 of the 111 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT06433752. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Rela | Trialion